vincenzo visco

Prof. Dr. vincenzo visco

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2011 in Knee Surgery, Sports Traumatology, Arthroscopy
Verified
Journal Article
Closed access
PDF file
VMVetrano Mario
Vetrano Mario
Federica D'AlessandroFederica D'Alessandro
Federica D'Alessandro
MTMaria Rosaria Torrisi
Maria Rosaria Torrisi
AFAndrea Ferretti
Andrea Ferretti
MVMaria Chiara Vulpiani
Maria Chiara Vulpiani
VVvincenzo visco
vincenzo visco

26 March 2009 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
VVvincenzo visco
vincenzo visco
FBFelice A. Bava
Felice A. Bava
Federica D'AlessandroFederica D'Alessandro
Federica D'Alessandro
MCMarco Cavallini
Marco Cavallini
VZVincenzo Ziparo
Vincenzo Ziparo
MTMaria Rosaria Torrisi
Maria Rosaria Torrisi

26 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLaura Leone
Laura Leone
VMVetrano Mario
Vetrano Mario
DRDanilo Ranieri
Danilo Ranieri
SRSalvatore Raffa
Salvatore Raffa
MVMaria Chiara Vulpiani
Maria Chiara Vulpiani
VVvincenzo visco
vincenzo visco
In vitro models of human tenocytes derived from healthy as well as from ruptured tendons were established, characterized and used at very early passage (P1) to evaluate the effects of Extracorporeal Shock Wave Treatment (ESWT). The molecular analysis of traditional tenocytic markers, including Scleraxis (Scx), Tenomodulin (Tnm), Tenascin-C (Tn-C) and Type I and III Collagens (Col I and Col III), permitted us to detect in our samples the simultaneous expression of all these genes and allowed us to compare their levels of expression in relationship to the source of the cells and treatments. In untreated conditions, higher molecular levels of Scx and Col I in tenocytes from pathological compared to healthy samples have been detected, suggesting – in the cells from injured tendon – the natural trigger of an early differentiation and repairing program, which depends by Scx and requires an increase in collagen expression. When ESWT (at the dose of 0.14 mJ/mm2) was applied to cultured tenocytes explanted from injured source, Scx and Col I were significantly diminished compared to healthy counterpart, indicating that such natural trigger maybe delayed by the treatment, in order to promote cellular repair. Herein, we show for the first time that ESWT enhances in vitro functional activities of ruptured tendon-derived tenocytes, such as proliferation and migration, which could probably contributes to tendon healing in vivo.

28 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
LLLaura Leone
Laura Leone
SRSalvatore Raffa
Salvatore Raffa
VMVetrano Mario
Vetrano Mario
DRDanilo Ranieri
Danilo Ranieri
FMFLORENCE MALISAN
FLORENCE MALISAN
VVvincenzo visco
vincenzo visco
Extracorporeal Shock Wave Treatment (ESWT) enhances the in vitro -induced differentiation of human tendon-derived stem/progenitor cells (hTSPCs)

27 February 2004 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
VVvincenzo visco
vincenzo visco
FBFrancesca Belleudi
Francesca Belleudi
Cinzia MarcheseCinzia Marchese
Cinzia Marchese
LLLaura Leone
Laura Leone
LALaura Aimati
Laura Aimati
MTMaria Rosaria Torrisi
Maria Rosaria Torrisi

28 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VMVetrano Mario
Vetrano Mario
DRDanilo Ranieri
Danilo Ranieri
MNMonica Nanni
Monica Nanni
APAntonio Pavan
Antonio Pavan
FMFLORENCE MALISAN
FLORENCE MALISAN
VVvincenzo visco
vincenzo visco
Novel strategies have been proposed for articular cartilage damage occurring during osteoarthritis (OA) and -among these- Extracorporeal Shock Wave Therapy (ESWT), intra-articular injections of Platelet-Rich Plasma (PRP) or Hyaluronic Acid (HA) revealed encouraging results. To investigate the possible mechanisms responsible for those clinical benefits, we established primary cultures of human chondrocytes derived from cartilage explants and measured the in vitro effects of ESW, PRP and HA therapies. After molecular/morphological cell characterization, we assessed those effects on the functional activities of the chondrocyte cell cultures, at the protein and molecular levels. ESWT significantly prevented the progressive dedifferentiation that spontaneously occurs during prolonged chondrocyte culture. We then attested the efficiency of all such treatments to stimulate the expression of markers of chondrogenic potential such as SOX9 and COL2A, to increase the Ki67 proliferation index as well as to antagonize the traditional marker of chondrosenescence p16INK4a (known as Cdkn2a). Furthermore, all our samples showed an ESW- and HA-mediated enhancement of migratory and anti-inflammatory activity onto the cytokine-rich environment characterizing OA. Taken together, those results suggest a regenerative effect of such therapies on primary human chondrocytes in vitro. Moreover, we also show for the first time that ESW treatment induces the surface expression of major hyaluronan cell receptor CD44 allowing the increase of COL2A/COL1A ratio upon HA administration. Therefore, this work suggests that ESW-induced CD44 overexpression enhances the in vitro cell susceptibility of human chondrocytes to HA, presumably favouring the repair of degenerated cartilage.